On January 9, 2026, AirNexis Therapeutics, a clinical-stage biotech company developing therapeutics for pulmonary diseases, announced the closing of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor in Phase 2 development for chronic obstructive pulmonary disease (COPD) from Haisco Pharmaceutical Group. The financing was led by founder Frazier Life Sciences, with participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital, and Enavate Sciences, among others.

Wilson Sonsini Goodrich & Rosati advised Frazier Life Sciences on patent matters related to the transaction.

The Wilson Sonsini team that advised Frazier Life Sciences was led by Val Zunic and Mike Hostetler and included Judy Pan and Kaia Parenti.

For more information, please see AirNexis Therapeutics’ news release. Additional coverage is available in Fierce Biotech.